Avelar, R. A., Gupta, R., Carvette, G., da Veiga Leprevost, F., Colina, J., Teitel, J., Nesvizhskii, A., O’Connor, C., Hatzoglou, M., & Difeo, A. (2024, March 28). Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A–TFE3–ATF4 pathway [Preprint].
Lee, R. T., Yang, P., Alahmadi, A., McQuade, J., Yuan, E., Difeo, A., Narla, G., & Kaseb, A. (2021). Mistletoe extract Viscum Fraxini-2 for treatment of advanced hepatocellular carcinoma: A case series. Case Reports in Oncology, 14(2), 729–738.
Nagaraj, A. B., Knarr, M., Sekhar, S., Connor, R. S., Joseph, P., Kovalenko, O., Fleming, A., Surti, A., Nurmemmedov, E., Beltrame, L., et al. (2021). The miR-181a–SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer. Cancer Research, 81(16), 4081–4095.
Huvila, J., Cochrane, D. R., Ta, M., Chow, C., Greening, K., Leung, S., Karnezis, A. N., Difeo, A., & Huntsman, D. G. (2021, November). STING pathway expression in low-grade serous carcinoma of the ovary: An unexpected therapeutic opportunity? The Journal of Pathology: Clinical Research, 7(6), 537–547.
O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020). Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene, 39(9), 1832–1847